<DOC>
	<DOC>NCT01366482</DOC>
	<brief_summary>The DEFINITIVE AR study is a prospective, multi-center, randomized pilot study evaluating the use of either the TurboHawk™ or SilverHawk® plaque excision systems followed by treatment with the Cotavance™ drug-eluting balloon catheter versus the Cotavance balloon catheter alone in patients with peripheral arterial disease.</brief_summary>
	<brief_title>Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Rutherford Clinical Category 24 At least 18 years of age Is able and willing to provide written informed consent prior to study specific procedures Has a life expectancy of less than 24 months Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing Has one or more of the contraindications listed in the SilverHawk/ TurboHawk or Cotavance IFUs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Peripheral arterial disease,</keyword>
	<keyword>claudication,</keyword>
	<keyword>atherectomy,</keyword>
	<keyword>plaque excision,</keyword>
	<keyword>drug-coated balloon</keyword>
	<keyword>drug-eluting balloon</keyword>
</DOC>